Clinical trial
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed…
NCT00217529 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00217529 |
|---|---|
| Title | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
| Official title | A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Biological, Drug |
| Interventions | pegfilgrastim, carboplatin, docetaxel, erlotinib hydrochloride |
| Start date | Jun 1, 2004 |
| Primary completion | Nov 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 21, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: